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The relative efficacy of different aminoglycosides or of different dosage schedules of
the same aminoglycoside should be quantitated and related to relative toxicity.
Quantitative experimental indicators of efficacy should not only include MIC and
MBC, but also the postantibiotic effect in vitro and in vivo, the emergence of
resistance in in-vitro and in-vivo models, and the relationship between plasma
concentration profiles and efficacy. Parameters of clinical efficacy are to be related to
pharmacokinetic parameters such as the ratio between the peak serum concentration
and the MIC.
Toxicity in clinical trials should be assessed by the most sensitive methods
available. Experimental and clinical studies have shown cortical uptake to be a
sensitive indicator of renal toxicity. As far as ototoxicity is concerned endolymph
and perilymph pharmacoldnetics are not dearly related. Chnical ototoxicity should
be assessed by sensitive methods, such as high frequency tone audiometry. Finally,
risk factors for nephrotoxicity and ototoxicity (e.g., duration of treatment, asso-
ciated nephrotoxk drugs, dehydration) should be assessed in the evaluation of
clinical trials.
Introduction
As there seems to be no qualitative difference between the various aminoglycosides with
respect to their antibacterial efficacy, much emphasis is laid on their relative toxicity
when it comes to the choice of a particular aminoglycoside. However, the criteria to be
used to compare quantitatively the toxic features of aminoglycosides, especially under
clinical conditions, have not been established systematically. Moreover, if quantified at
all, they should be evaluated in relation to the efficacy. This review is intended to
discuss accepted methods to quantify efficacy and toxicity, in a way to optimize the
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proper choice of an aminoglycoside. It is concluded that data are still insufficient to
allow for a definite choice. For instance, any modification in the dose or dosage
regimen of a drug that lessens toxicity may also reduce the drug's therapeutic efficacy.
This is especially true for the aminoglycosides since their therapeutic index is narrower
than that observed with /Mactam antibiotics, for example. Although some members of
the aminoglycoside family have been available since the early days of antibiotic
therapy, it is only during the last decade that new insights have been provided into the
pharmacodynamic activity of these drugs. Those new insights are the focus of discus-
sion in this review.
Efficacy
The time-honoured method of assessing the antibacterial activity of the aminoglyco-
sides is by measurement of the MIC and the MBC. Although these values are
influenced by the concentration of divalent cations, the pH of the medium, and the
inoculum (Reller et al., 1974; Thrupp, 1986), standardized techniques provide reason-
able accuracy for these measurements. The activity of the aminoglycosides in human
serum is virtually identical to that in broth with similar cation content, and this
provides the rationale for using serum bactericidal activity as an indication of efficacy
(Stratton & Reller, 1977; Van/der Auwera & Klastersky, 1987). Parameters such as the
MIC and MBC give only a partial view of the full pharmacodynamic activity of these
drugs. The MBC does not provide the bactericidal rate or show whether the latter is
enhanced by increasing concentrations. Furthermore, the MIC does not reveal whether
drugs exhibit persistent suppression of bacterial growth after antibiotic exposure, a
phenomenon referred to as the postantibiotic effect or PAE (Vogelman & Craig, 1985;
Craig & Gudmundsson, 1986). In fact, the rate of bactericidal activity with increasing
concentrations and the presence or absence of a postantibiotic effect (PAE) better
describe the time course of antimicrobial activity than MIC or MBC.
Aminoglycoside antibiotics differ from /Mactams in that their bactericidal activity is
rapid, and concentration-dependent over a much wider range of concentrations. This
has been shown to be so in vitro (Shah, Junghanns & Stille, 1976; Van der Auwera &
Klastersky, 1987) as well as in vivo (Vogelman & Craig, 1986; Flueckiger, Feller &
Gerber, 1986). On the other hand, MacArthur et al. (1984) have suggested that killing
by aminoglycosides is concentration-dependent only during the first hour and that this
stage is followed by a fixed limited bactericidal rate which is not enhanced by increasing
concentrations. This may be so, but studies with repeated doses of aminoglycosides in
neutropenic mice have demonstrated concentration-Hdependent killing for several hours
at least (Gudmundsson, Turnidge & Craig, 1982; Vogelman et al., 19886).
Aminoglycoside antibiotics produce PAEs against staphylococci and various Gram-
negative bacilli (Vogelman & Craig, 1985; Craig & Gudmundsson, 1986; Van der
Auwera & Klastersky, 1987). In general, the duration of the PAE increases with longer
exposure times or higher drug concentrations up to a maximal response. Although the
rapid and relatively complete bactericidal activity of aminoglycosides against many
bacteria makes it difficult to quantitate a maximal response, PAEs of 1-3 h have
consistently been observed in vitro, both in broth and in human serum. In vivo, even
longer PAEs (4-8 h) have been observed with Staphylococcus aureus, Klebsiella pneumo-
nia*, and Pseudomonas aervginosa (Craig & Gudmundsson, 1986; Vogelman et al.,
1988a). These pharmacodynamic characteristics of the aminoglycosides, namely con-
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centration-dependent bactericidal activity and the presence of prolonged postantibiotic
suppression of bacterial growth, provide the therapeutic rationale for less frequent
dosing of these drugs than in current clinical practice. The administration of large
intermittent doses would produce high peak levels which might maximize the rate of
killing, and the PAE would maintain efficacy when serum and tissue levels fell below
the minimal effective concentration. Blaser, Stone & Zinner (1985) used an in-vitro
model, simulating human pharmacokinetics, to examine the efficacy of several aminog-
lycoside dosage regimens against staphylococci and Gram-negative bacilli. When
combined with ceftazidime, netilmicin was as effective in this model when given as a
single daily dose as when administered in three daily doses that provided 50% more
total dosage per day (Blaser et al., 1985). Emergence of resistance did not occur during
the combination therapy. Netilmicin alone as a once-daily administration was also
superior to either a continuous infusion or an 8-h regimen of the same total dose per
24 h, in terms of faster killing and greater reduction of bacterial numbers. Regimens
that did not provide peak levels of at least ten times the MIC were associated with the
selection of resistant subpopulations (Blaser et al., 1987). The emergence of aminogly-
cosidc-resistant subpopulations during therapy has also been observed in vivo in normal
and neutropenic mice (Gerber et al., 1982; Pechere et al., 1986). These observations
provide another reason for maximizing the peak level by intermittent dosing.
There are a variety of animal studies that have compared the efficacy of continuous
infusion or frequent dosing with infrequent (as long as once daily) administration of
the same amount of aminoglycoside. No difference in outcome was observed against
P. aeruginosa in rabbit endocarditis (Powell et al., 1983), chronic pneumonia in rats
(Powell et al., 1983), acute pneumonia in guinea pigs (Kapusnik et al., 1988), peritonitis
in rats (Mordcnti, Quintiliani & Nightingale, 1985), and thigh infection in neutropenic
mice (Gerber et al., 1983). Infrequent dosing was more effective than continuous
infusion or frequent bolus administration in acute pseudomonas pneumonia in guinea
pigs (Powell et al., 1983) and in staphylococcal endocarditis in rabbits, in combination
with nafcillin (Kapusnik & Sande, 1986). On the other hand, 12- and 24-h dosages of
tobramycin were less effective than 4- and 8-h dosing regimens in a klebsiella pneu-
monia model in mice (Pechere, Lctarte & Pechere, 1987). Similar findings were
observed with 4-h and 24-h dosing of tobramycin in pseudomonas pneumonia in
neutropenic guinea pigs (Kapusnik et al., 1988). Conclusions drawn from experimental
studies focusing on dosage intervals are limited by the fact that in small animals the
drugs are eliminated at a much faster rate than in man. In simulated human pharma-
cokinetics, in both normal and granulocytopenic mice, it was demonstrated that a
simulation of once daily administration to man of netilmicin (in combination with /?-
lactam drugs) was superior or at least equal to a simulation of a thrice-daily regimen
(Kozak et al., 1985; Gerber et al., 1986).
Four human trials have found no statistical difference in outcome between once daily
and 8-hourly administration or continuous infusion (Powell et al., 1983; Nordstrom et
al., 1985) and between continuous infusion and 6-hourly dosing (Feld et al., 1977; Feld
et al., 1984). However, none of these animal and human studies was designed to
correlate specific pharmacokinetic parameters with efficacy. Several clinical studies
involving patients with Gram-negative bacillary infections have demonstrated that
peak serum bactericidal titres of at least 8 (Klastersky, Meunier-Carpentier & Prevost,
1977; Sculier & Klastersky, 1984), or peak serum concentrations greater than 5 mg/1 for
gentamicin and tobramycin and greater than 20 mg/1 for amikacin (Noone et al., 1974;
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Moore, Smith & Lietman, 1984) were associated with a significantly improved clinical
response. Since bactericidal titres will be strongly correlated with both antibiotic
concentration and sensitivity of causative micro-organisms, they should be expected to
correlate more strongly with clinical outcome than serum concentrations alone. Indeed,
in a reanalysis of their data, Moore, Lietman & Smith (1987) observed that the ratio of
the peak concentration to the MIC was the major determinant of the clinical response
to aminoglycoside therapy. At maximum peak concentration: MIC ratios of 6:1 or less
the average response rate was less than 70%, as opposed to a clinical response rate of
approximately 90% at ratios of 8:1 or higher.
Since each of the studies mentioned above used a narrow range of doses, adminis-
tered primarily at one dosing frequency, it cannot be determined whether the peak drug
level is the critical parameter or whether a higher peak concentration simply reflects a
larger area under the concentration-versus-time curve (AUC) and persistence of
inhibitory or bactericidal levels for a greater proportion of the dosage interval. By using
a large number of dosing regimens in the neutropenic mouse-thigh model, Vogelman et
al. (19886) were able to reduce much of the interdependence among pharmacokinetic
parameters and determine the parameter that correlated best with efficacy. Their
studies demonstrated that the AUC or the total dose, rather than the peak level or the
duration of inhibitory serum levels, was the major determinant of the efficacy of
aminoglycosides against Gram-negative bacilli. However, efficacy was reduced when
the dosing interval was longer than the time period during which serum levels exceeded
the MIC plus the duration of the postantibiotic effect, both as determined in vitro.
In conclusion, the pharmacodynamic characteristics of the aminoglycosides allow for
equal efficacy with a variety of different dosing regimens. Although the AUC or total
dose appears to be the primary determinant of efficacy, peak levels greater than ten
times the MIC may be advantageous in preventing the selection of aminoglycoside
resistant subpopulations. The studies cited provide support for a once-daily aminogly-
coside dosing regimen, but there are still insufficient data on the effectiveness of such a
regimen in human infections.
Toxicity
Although the toxicity of aminoglycosides is distinguished as nephrotoxicity on the one
hand, and ototoxicity and vestibulotoxicity on the other, these two aspects are clearly
interwoven, in so far as the risk for ototoxicity increases with impaired renal function.
Insights into ototoxicity, and especially vestibulotoxicity, are still less developed than
those into renal toxicity, mainly because the site of the toxic lesion is less accessible.
Nephrotoxicity certainly limits the clinical utility of aminoglycosides (Lietman, 1985).
Therefore, the identification of factors associated with a greater incidence of renal
damage is critical. Potential risk factors can be classified as those related to the drug
and its administration and those related to the clinical condition of the patient
(Table I).
Aminoglycosides are highly polar drugs which cross biological membranes poorly or
not at alL but they are filtered by the glomerulus. After entering the luminal fluid of the
proximal renal tubule a small portion of the total filtered drug is reabsorbed and stored
in the proximal tubular cells. After charge-mediated binding, the drug is taken up into
the cell in small invaginations of the cell membrane, by a mechanism called 'carrier
mediated pinocytosis' (Collier, Lietman & Mitch, 1979). Within one hour after injec-
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tion, the drug is translocated into apical cytoplasmic vacuoles (Silverblatt & Kuehn,
1979). These endocytic vesicles fuse with lysosomes, sequestering the aminoglycosides
inside those organelles in an unchanged form. Since pinocytosis is a continuing
phenomenon aminoglycosides tend to accumulate extensively inside the lysosomes. The
lysosomes have been identified as the first organelles to show alterations during
aminoglycoside treatment (De Broe et al., 1984). Once trapped in the lysosomes of
proximal tubular cells aminoglycosides inhibit lysosomal phospholipases and
sphingomyelinase (Laurent et al., 1982; Giuliano et al., 1984), resulting in lysosomal
phospholipidosis, with a non-specific accumulation of polar phospholipids in myeloid
bodies. Once a threshold in cortical drug concentration is reached, the lysosomal
phospholipidosis progresses and the overloaded lysosomes continue to swell even in the
absence of any further drug administration. This may result in the loss of integrity of
the restricting membranes of lysosomes and release of large amounts of aminoglyco-
sides, lysosomal enzymes and phospholipids into the cytosol. The extralysosomal
aminoglycosides can gain access to other organelles, disturbing their functional integ-
rity which may lead to cell death (Tulkens et al., 1984).
The nephrotoxicity of aminoglycosides is determined by two major variables: (a) the
intrinsic potential of the drug to damage subcellular structures and (b) the amount of
drug accumulation in the renal cortex (Kaloyanides & Pastoriza-Munoz, 1980).
Any factor that increases the renal uptake of aminoglycosides is a risk factor for
nephrotoxicity. The duration of exposure of the proximal tubular cells to aminoglyco-
sides is a critical factor since it determines the extent of drug uptake. Persistent
exposure undoubtedly results in increased renal drug levels. Dosage regimen is another
important determinant of the extent of cortical aminoglycoside concentrations. Experi-
mental nephrotoxicity caused by gentamicin is more severe when the total daily dose is
divided or given by continuous infusion than when it is given as a single bolus (Frame
et al., 1977; Reiner, Bloxham & Thompson, 1978; Powell et al., 1983). The reason for
this may be found in the renal cortical uptake-storage kinetics of various aminoglyco-
sides (Giuliano et al., 1986). In the rat, steady-state elevations of serum gentamicin and
netilmicin are associated with a nonlinear increase in renal cortical levels, strongly
Table L Potential risk factors for aminoglycoside
nephrotoxicity (De Broe, 1985)
Drug-related
Dose
duration
dosage regimen
Prior aminoglycoside
treatment
Choice of drug
Associated drugs
diuretics
cyclosporin
cisplatin
amphotericin
Patient related
Age
Prior renal insufficiency
Hepatic insufficiency
'Critically ill' patient
Sodium-volume depletion
Other causes
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suggesting saturable uptake while cortical uptake of tobramycin is linearly related to
serum concentrations. These findings imply for gentamicin and netilmicin that the
fraction of drug taken up by proximal tubule cells is higher when the same amount of
drug is given by continuous infusion than by intermittent or single injections. Cortical
uptake of tobramycin, in the rat, is independent of the dosage schedule, agreeing with
the linear uptake kinetics of this aminoglycoside.
In humans, in a study in renal cancer patients who underwent nephrectomy, a critical
effect of dosage schedule on renal uptake of gentamicin and netilmicin was found. In
those patients a single injection resulted in 30% and 50% lower cortical drug concen-
trations of netilmicin and gentamicin, respectively, than the administration of the same
amount of drug by a 24-h continuous infusion (Verpooten et al., 1989). Although an
impressive number of comparative studies of aminoglycoside nephrotoxicity in humans
are available (Whelton, 1985), it is difficult to draw firm conclusions from these studies
because of the multiple clinical variables and because most of the studies failed to
achieve critical methodological standards. Very often detection of clinical nephrotoxi-
city was based on proving decreased glomerular filtration in the individual patient. This
led to high threshold values, resulting in underestimation of minor damage. In
comparative clinical studies, statistical analysis of parameters of glomerular filtration
(e.g., serum creatinine) in different groups of patients would be much more sensitive in
detecting minor differences between different aminoglycosides. In a short-term prospec-
tive, controlled, randomized, comparative study in humans using clinical dosage
regimens, gentamicin, tobramycin and netilmicin could not be distinguished on the
basis of either tissue accumulation or early drug-induced cellular effects (De Broe et al.,
1983). Advanced age has been suggested as a risk factor for aminoglycoside nephro-
toxicity, as aging is accompanied by a decreased capacity in renal function and a
marked decline of the regenerative response to drug-induced cell injury.
Pre-existing renal disease does not appear to be a risk factor for the induction of
further renal impairment by aminoglycosides. Adjusting the dose or extending the
interval between doses is not very difficult and can be accomplished reliably with the
use of simple nomograms or with computer programs. Although monitoring of serum
levels remains mandatory, gross deviations from desired plasma concentrations are
rarely observed when dose adjustment procedures are being used. Since in most clinical
trials this precaution has been taken, it may have contributed to the apparent lack of
risk in renal failure patients. Moreover, it was shown experimentally that in rats with
chronic renal failure less aminoglycoside is accumulated than in normal rats at
comparable serum concentrations (Verpooten et al., 1986; Pattyn et al., 1988).
Finally, a prospective clinical study has shown that liver disease is associated with the
development of nephrotoxicity. Hepatic insufficiency leading to intra-renal vasocon-
striction, reduced renal blood flow and stimulation of the renin-angjotensin system is
the proposed pathophysiological mechanism (Moore et al., 1984).
The assessment of ototoxicity by conventional means, in clinical studies on aminog-
lycoside treated patients as well as in clinical practice, appears clearly inadequate.
Careful clinical monitoring of hearing and vestibular functions is mandatory, but
irreversible anatomical damage may have occurred before symptoms appear. More-
over, problems may arise for the first time days or even weeks after the treatment has
ended. Conventional audiograms also lack sensitivity, since they omit the higher
frequencies, the first to be affected by aminoglycosides (Tange et al., 1982). Three new
approaches have recently been introduced to improve early detection, but none is
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perfect. Brain stem evoked response audiometry (BERA) is a non-invasive, objective
and sensitive method by which minute cochlear lesions might be recognized at a
reversible stage (Pechere & Bernard, 1982). As BERA requires no active participation
from the patient, it can be used in neonates, infants and comatose individuals.
Limitations of the method include relatively high costs for performing the test, the need
for a reference recording in the individual patients before therapy and the multiple
interferences of anoxia, neurological disorders, intubation, agitation of the patient, etc.
Also, the actual significance of altered recordings at the anatomical and physiological
level remains uncertain, so that interpretation is difficult, notably in neonates. Electro-
cochleography is another objective technique but the need to put an electrode through
the ear drum limits its clinical application. High frequency tone audiometry is indeed
very promising for patients who can actively respond to this subjective method
(Dreschler et al., 1985; Tange, Dreschler & Van der Hulst, 1985). Ototoxic alterations
can be shown while the patient does not yet complain of hearing loss or tinnitus
(Jacobson, Downs & Fletcher, 1969). However, again reference testing has to be done
before therapy when the patient is often too ill for reliable responses to be obtained.
The same holds true for the methods available for monitoring the vestibular function.
The pharmacokinetics of aminoglycosides in the inner ear have recently been
clarified. It was shown that the uptake of gentamicin, netilmicin and amikacin into
different inner ear tissues did not correlate with the degree and the anatomical
specificity of toxicity (Dulon et al., 1986), indicating a very specific cellular target (Aran
et al., 1988). It was also observed that ototoxicity and nephrotoxicity induced by
gentamicin did not correlate (Dulon et al., 1988a). Moreover, it was also demonstrated
that cochlear damage induced by gentamicin was not associated with an accumulation
of the drug into the inner ear (Tran Ba Huy, Bernard & Schacht, 1986). The uptake of
gentamicin by these tissues, however, is dose-dependent and manifests rapid saturation
kinetics, followed by a concentration plateau and a very slow release. As a conse-
quence, the prolonged exposure of the hair cells to the aminoglycoside probably
accounts for the damage. Comparisons of different aminoglycosides with regard to
their respective ototoxicity still poses problems, notably since the differences in
nephrotoxicity are often not taken into account in animal studies. However, it has been
shown experimentally that toxicity towards the cochlear and the vestibular portions
may vary between drugs (Aran et al., 1982). Streptomycin is essentially vestibulotoxic,
while amikacin is exclusively cochleotoxic. Gentamicin and tobramycin attack both
targets, although the latter is somehwat less vestibulotoxic. Dibckacin has similar
vestibulotoxicity to tobramycin, but exhibits little cochleotoxicity; netilmicin shows no
cochleotoxicity and little vestibulotoxicity (Aran et al., 1982). The reasons /or these
quantitative differences remain unclear, as the structure of the two receptor organs is
very similar, and the differential toxicity is not correlated with differential uptake of
drug. In-vitro studies dealing with separate hair cells (Brownell et al., 1985; Zenner,
Zimmermann & Schmitt, 1985; Dulon et al., 19886), as well as uptake studies at the
cellular level using immunohistology and autoradiography, indicate indeed that the
aminoglycosides interfere specifically with the hair cells (Hayasnida et al., 1985; Aran et
al., 1988).
Very few reports have addressed the issue of the ototoxicity with regard to dosage
schedules. These studies are limited by ethical problems when conducted on patients,
and by dosing problems when carried out in experimental animals. Dosages used in
animals are multiples of those used in humans in terms of mg/kg, and even in terms of
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rag/body area, and hence are difficult to extrapolate to the clinical situation. In
addition, different dosage schedules may have different impacts on renal function,
which, in turn can impair the inner ear through the accumulation kinetics. These
considerations might explain apparently conflicting experimental results. In rats moni-
tored by brain stem evoked potentials, two or three daily doses appeared more
vestibulo- and cochleotoxic than the same total dose given once a day (Pechere &
Bernard, 1984). Similar results were found in guinea pigs (Brummett & Fox, 1982). In
contrast, Davis et al. (1984), found experimentally that the magnitude of kanamycin
ototoxicity was related to the total daily dose alone and not to the dosing schedule.
With gentamicin, however, the dosage regimen does affect the uptake of drug by the
inner ear. Less antibiotic penetrates into the cochlear tissues and fluids after a single
intramuscular injection than after equal doses administered as a continuous infusion
(Tran Ba Huy, Bernard & Schacht, 1986). Thus, it may well be that wider dosing
intervals produce less inner ear damage even though, in the latter study, the uptake of
gentamicin was not directly correlated with toxicity. In patients with cystic -fjbrosis no
differences with regard to ototoxicity were seen when the same daily dose of tobra-
mycin was given for about ten days either by continuous infusion or by once daily
dosing (Powell et al., 1983).
In humans, ototoxicity can be only poorly predicted from serum concentrations.
Some older studies suggested a correlation between peak or trough serum aminoglyco-
side concentrations and ototoxicity. In a retrospective study on tuberculous patients, it
was found that high trough levels of streptomycin predisposed to ototoxicity but those
patients who had elevated trough levels were also older and had impaired renal
function (Line, Poole & Waterworth, 1970). Nordstrom et al. (1973) showed a
significant correlation between high trough levels of gentamicin and ototoxicity, in a
well conducted prospective study, but toxicity also correlated with high total dosage,
longer duration of therapy and, once again, with abnormal renal function. Black et al.
(1976), in monitoring for ototoxicity patients treated with amikacin, found that 57% of
patients with a peak serum concentrations exceeding 32 mg/1, and 55% of patients with
trough concentrations exceeding 10 mg/1, developed cochlear damage. However, the
group with high frequency hearing loss received a larger mean total dose and were
treated for a longer period than the patients without audiometric changes. It is
sometimes suggested that the area under the time concentration curve, rather than peak
or trough values might be a major risk factor for ear damage (Barza & Lauermann,
1978), but there are no experimental or clinical studies substantiating this hypothesis.
On the other hand, a specific threshold for peak or trough concentrations of aminogly-
cosides, above which ototoxicity occurs, can also not be identified: severe damage can
occur in individuals with 'normal' serum concentrations and sometimes in a very
unexpected and brutal fashion. The experimental and clinical studies with less frequent
dosing schedules, in keeping the same daily dose, as described above, tend to obscure
the correlations between serum levels and ototoxicity found previously. However,
increased serum half-life, peak concentrations, trough concentrations or area under the
time concentration curve may reflect impaired renal function, which is a recognized risk
factor of ototoxicity.
In conclusion, there are experimental and clinical data that suggest that variation of
dosage regimens may broaden the therapeutic index of aminoglycosides. Decreased
dosage frequency may decrease nephro- as well as oto- and vestibulotoxicity of
aminoglycosides, although tobramycin might be an exception to the rule. On the other
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hand experimental data suggest that efficacy is at least not decreased by increasing the
dosage interval. Clinical data are still insufficient to draw strong conclusions, either
about the equal efficacy of decreased dosage frequency, or about nephro- and ototoxi-
city. Part of the lack of clinical data on toxicity may be the result of inadequate use of
available methods, including statistical sophistication, to make satisfactory use of the
data. Future clinical trials should determine multiple pharmacokinetic parameters in
patients (e.g., peak level, ratio of peak to MIC, AUC, AUC above MIC, and duration
of inhibitory serum levels) so that multiple variate analysis can identify the major
parameters determining efficacy. These studies should also look closely for resistant
subpopulations by direct plating of clinical specimens on aminoglycoside-containing
plates. They should also concentrate on the use of refined clinical methods to detect
toxicity.
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